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Background: The detection of circulating tumor cells (CTCs) in peripheral blood (PB) of patients with breast cancer
predicts poor clinical outcome. Cancer cells with stemness and epithelial-to-mesenchymal transition (EMT) features
display enhanced malignant and metastatic potential. A new methodology was developed in order to investigate
the co-expression of a stemness and an EMT marker (ALDH1 and TWIST, respectively) on single CTCs of patients
with early and metastatic breast cancer.
Methods: Triple immunofluorescence using anti-pancytokeratin (A45-B/B3), anti-ALDH1 and anti-TWIST antibodies
was performed in cytospins prepared from hepatocellular carcinoma HepG2 cells and SKBR-3, MCF-7 and MDA.
MB.231 breast cancer cell lines. Evaluation of ALDH1 expression levels (high, low or absent) and TWIST subcellular
localization (nuclear, cytoplasmic or absent) was performed using the ARIOL system. Cytospins prepared from
peripheral blood of patients with early (n = 80) and metastatic (n = 50) breast cancer were analyzed for CTC detection
(based on pan-cytokeratin expression and cytomorphological criteria) and characterized according to ALDH1 and
TWIST.
Results: CTCs were detected in 13 (16%) and 25 (50%) patients with early and metastatic disease, respectively. High
ALDH1 expression (ALDH1high) and nuclear TWIST localization (TWISTnuc) on CTCs was confirmed in more patients with
metastatic than early breast cancer (80% vs. 30.8%, respectively; p = 0.009). In early disease, ALDH1low/neg CTCs
(p = 0.006) and TWISTcyt/neg CTCs (p = 0.040) were mainly observed. Regarding co-expression of these markers,
ALDH1high/TWISTnuc CTCs were more frequently evident in the metastatic setting (76% vs. 15.4% of patients, p = 0.001;
61.5% vs. 12.9% of total CTCs), whereas in early disease ALDH1low/neg/TWISTcyt/neg CTCs were mainly detected (61.5% vs.
20% of patients, p = 0.078; 41.9% vs. 7.7% of total CTCs).
Conclusions: A new assay is provided for the evaluation of ALDH1 and TWIST co-expression at the single CTC-level in
patients with breast cancer. A differential expression pattern for these markers was observed both in early and
metastatic disease. CTCs expressing high ALDH1, along with nuclear TWIST were more frequently detected in patients
with metastatic breast cancer, suggesting that these cells may prevail during disease progression.* Correspondence: kalergi@med.uoc.gr
†Equal contributors
1Laboratory of Tumor Cell Biology, School of Medicine, University of Crete,
GR-71110 Heraklion, Crete, Greece
Full list of author information is available at the end of the article
© 2014 Papadaki et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Papadaki et al. BMC Cancer 2014, 14:651 Page 2 of 10
http://www.biomedcentral.com/1471-2407/14/651Background
Circulating tumor cells (CTCs) have been identified in
peripheral blood (PB) of patients with breast cancer and
their presence has been associated with poor disease
outcome [1-4]. It has been suggested that CTCs are ex-
tremely heterogeneous and that they include the popula-
tion of cells giving rise to overt metastases [5]. Therefore
further characterization of CTCs at the single cell level
would be of utmost importance in order to understand
their individual biologic role.
Several studies in many tumor types, including breast
cancer, reported that there is a subset of cells with stem-
ness properties, named cancer stem cells (CSCs). These
cells are proposed to display enhanced malignant and
metastatic potential [6-8]. Tumor cells with increased
activity of the detoxifying enzyme aldehyde dehydrogen-
ase (ALDH) are considered as putative breast CSCs, due
to their self-renewal capacity as shown by serial passages
in Nonobese Diabetic/Severe Combined Immunodefi-
ciency (NOD/SCID) mice and their ability to regenerate
the cellular heterogeneity of the initial tumor [9]. Gines-
tier et al., showed a correlation between ALDH activity
and ALDH1 expression in breast cancer cells [10].
Moreover, the expression of ALDH1 in primary tumors
has been associated with poor prognosis in patients with
breast cancer [10-12]. We, among others, have recently
reported that CTCs expressing ALDH1 are detectable in
patients with metastatic breast cancer, suggesting that
this “stemness phenotype” could be related to metastases
formation [13,14].
There is growing evidence suggesting that both
tumor growth and metastatic dissemination take place
through a phenotypic modulation known as epithelial-
to-mesenchymal transition (EMT), a process by which
tumor cells lose their epithelial characteristics and acquire
a mesenchymal phenotype [15,16]. TWIST, a basic helix-
loop-helix transcription factor has been proposed among
others as a putative biomarker for EMT [17,18]. A positive
association between the expression of TWIST in primary
tumors and the risk for recurrence and poor survival has
been shown in breast cancer [19-21]. Moreover, we have
recently reported that TWIST expressing CTCs are fre-
quently observed in patients with breast cancer [22,23],
suggesting that cancer cells might undergo EMT during
vessel invasion, circulation and migration to metastatic
sites.
Recent studies have shown a direct link between CSCs
and EMT in breast cancer, suggesting that EMT gener-
ates cancer cells with stem cell-like traits [24-26]. Co-
expression of stem cell and EMT markers at the mRNA
expression level has been shown on CTCs of breast can-
cer patients [27,28]; however, this has not been demon-
strated on single CTCs as yet. Taking into account the
considerable heterogeneity of CTCs, the presence ofboth stemness and EMT characteristics on individual
CTCs could distinguish a population of cells with en-
hanced metastatic potential.
In the present study we developed a new methodology
using the ARIOL system, in order to evaluate the protein
expression pattern of a putative stemness (ALDH1) and
an EMT (TWIST) marker on CTCs of early and meta-
static breast cancer patients. We aimed to investigate
the co-expression of these markers at the single CTC-
level and to evaluate the incidence of distinct CTC sub-
populations in early and metastatic disease.
Methods
Patient samples
Peripheral blood (10 ml) was obtained from patients
with early (n = 80) and metastatic (n = 50) breast cancer,
before the initiation of adjuvant and first-line chemo-
therapy, respectively. In order to avoid contamination
with epithelial cells derived from the skin, blood was ob-
tained at the middle of vein Ppuncture, after the first
5 ml were discarded. Peripheral blood mononuclear cells
(PBMCs) cytospins were prepared and stored until use.
In the current study, prospectively collected cytospins
were analyzed. Peripheral blood was also obtained from
healthy blood donors (n = 20). All patients and healthy
volunteers gave their written informed consent to par-
ticipate in the study, which has been approved by the
Ethics and Scientific Committees of the University Gen-
eral Hospital of Heraklion, Crete, Greece.
Cytospin preparation
PBMCs were isolated by Ficoll-Hypaque density gradient
(d = 1,077 gr/mol) centrifugation at 1.800 rpm for 30 min.
PBMCs were washed two times with phosphate-buffered
saline (PBS) and centrifuged at 1.600 rpm for 10 min. Ali-
quots of 250.000 cells were cyto-centrifuged at 2.000 rpm
for 2 min on glass slides. Air-dried cytospins were stored
at −80°C.
Cell cultures
All cell lines were obtained from American Type Culture
Collection (ATCC). The HepG2 (human liver hepatocel-
lular carcinoma), MCF-7 and MDA.MB.231 cells were
cultured in high glucose GlutaMAX(™) Dulbecco’s
Modified Eagle Medium (DMEM) (GIBCO-BRL Co,
MD, USA), supplemented with 10% fetal bovine serum
(FBS) (GIBCO-BRL) and 1% penicillin/streptomycin
(GIBCO-BRL). MCF-7 cell culture medium was add-
itionally supplemented with 0.28% insulin. SKBR-3 cells
were cultured in high glucose GlutaMAX(™) McCoys5A
medium (GIBCO-BRL) supplemented with 10% FBS and
1% penicillin/streptomycin. Cells were maintained in a
humidified atmosphere of 5% CO2- 95% air at 37°C.
Subcultivation of all cell lines was performed using
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(EDTA) (GIBCO-BRL).
Immunofluorescence assay
PBMCs’ cytospin preparations were triple-stained with
pan-cytokeratin, ALDH1 and TWIST. Cytokeratin-positive
cells were detected using the A45-B/B3 anti-mouse anti-
body (recognizing the CK8, CK18 and CK19; Micromet,
Munich, Germany). PBMCs’ cytospins were also double-
stained with pan-cytokeratin and CD45 (common leu-
kocyte antigen), in order to exclude possible ectopic ex-
pression of cytokeratins in hematopoietic cells, as
previously described [29,30]. As proposed by Meng et al.
[31], the cytomorphological criteria of high nuclear to
cytoplasmic ratio and size larger than white blood cells,
were also employed in order to characterize a cytokeratin-
positive cell as a CTC.
PBMCs’ cytospin preparations were fixed with 3% (v/v)
paraformaldehyde (PFA) in PBS for 30 min and perme-
abilized with 0.5% Triton X-100 in PBS for 10 min at
room temperature (RT). After an overnight blocking
with PBS supplemented with 1% Bovine Serum A (BSA)
at 4PoPC, cells were double-stained for pan-cytokeratin/
CD45 or triple-stained for pan-cytokeratin/ALDH1/
TWIST. The incubation time for all primary and sec-
ondary antibodies was 1 h and 45 min, respectively.
Zenon technology (FITC-conjugated IGg1 antibody)
(Molecular Probes, Invitrogen) was used for the detec-
tion of pan-cytokeratin (A45-B/B3 anti-mouse antibody).
CD45 was detected using an anti-rabbit antibody (Santa
Cruz, CA, USA) labelled with Alexa 555 (Molecular
Probes, Invitrogen, Carlsbad, CA, USA); ALDH1 was de-
tected using an anti-mouse antibody (Abcam, Cambridge,
UK) labelled with Alexa 555 (Molecular Probes); TWIST
was detected using an anti-rabbit antibody (Abcam) la-
belled with Alexa 633 (Molecular Probes). Cells were
post-fixed with 3% (v/v) PFA in PBS for 15 min at RT.
Dapi-antifade reagent (Invitrogen) was finally added to
each sample for cell nuclear staining.
A total of 500.000 PBMCs per patient were analyzed
using the ARIOL system CTCs software (Genetix, UK)
as previously described [22]. Results are referred to pa-
tients with detectable CTCs only and are expressed as
number of CTCs/500.000 PBMCs.
Evaluation of sensitivity and specificity of CTC detection
The sensitivity of CTC detection using the current
methodology was evaluated by two separate approaches;
MCF-7, SKBR-3 and MDA.MB.231 breast cancer cells
were spiked into separate aliquots of 10 ml peripheral
blood obtained from ten healthy female blood donors, at
a concentration of 1, 10 and 100 cells per ml. Further-
more, MCF-7 cells were spiked into separate aliquots of
10*106 PBMCs from healthy volunteers, at a concentrationof 1, 10 and 100 cells per 1*106 PBMCs. All samples were
processed as previously described for patients’ samples.
To determine the specificity of CTC detection, periph-
eral blood was obtained from ten healthy donors and
samples were also processed as described above. Fur-
thermore, cytospins of HepG2 cells spiked into healthy
donors’ PBMCs (100/250.000 PBMCs) were used as
positive and negative controls in order to evaluate the
specificity of all antibodies. Negative controls were pre-
pared by omitting the corresponding primary antibody
and adding the secondary IgG isotype antibody.Evaluation of ALDH1 and TWIST expression in cancer cell
lines using the ARIOL system
Cytospins prepared from all cell lines were triple stained
with anti-pancytokeratin, anti-ALDH1 and anti-TWIST
antibodies and analyzed with the ARIOL system. Positive
and negative controls for each antibody were also
prepared.
HepG2 cell line was used as positive control for
ALDH1 expression, as proposed by the manufacturer. A
differential expression of ALDH1, varying from absent
to high was evident among these cells. In order to define
the cut-offs between high, low and absent ALDH1 ex-
pression, 50 randomly selected microscope vision fields
were analyzed and a total of 1.500 cells presenting high,
low or no ALDH1 expression (500 cells each) were mea-
sured by the ARIOL system. Measurements represent
the exposure time required for the detection of ALDH1
fluorescent signal. Using the resulting cut-offs, ALDH1
expression was further evaluated in three representative
human breast cancer cell lines: SKBR-3, MCF-7 and
MDA.MB.231 (Table 1).
HepG2 cells were also used as positive control for
TWIST expression, since they co-expressed ALDH1 and
TWIST. A differential TWIST subcellular localization in
nucleus and/or cytoplasm could be observed. In this
study, TWIST was characterized as cytoplasmic when
localized exclusively in the cytoplasm, and as nuclear
when localized in the nucleus, regardless of its co-
localization in the cytoplasm. Evaluation of TWIST ex-
pression was subsequently performed in SKBR-3, MCF-7
and MDA.MB.231.Statistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics version 20. Chi-square test was used to compare
the frequency of CTC phenotypes among early and
metastatic breast cancer patients. Mann Whitney test
was used to compare the incidence of CTCs with differ-
ent phenotypes per patient between early and metastatic
disease. Spearman’s rho analysis was used to investigate
the correlation between specific phenotypes among
Table 1 Quantification of ALDH1 expression levels in cancer cell lines using the ARIOL system
ALDH1 expression
levels
HepG2 SKBR3 MCF7 MDA.MB.231
Range Median ± SEa Range Median ± SEa Range Median ± SEa Range Median ± SEa
High 5 – 25 15 ± 0.25 10 – 25 15 ± 0.23 20 – 25 20 ± 0.11 15 – 25 20 ± 0.18
Low 30 – 55 45 ± 0.30 35 – 55 45 ± 0.29 35 – 55 45 ± 0.29 30 – 55 45 ± 0.29
Negative 60 – 90 70 ± 0.30 60 – 90 80 ± 0.39 60 – 90 75 ± 0.29 60 – 100 80 ± 0.46
aSE: standard error.
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at the 0.05 level.
Results
Sensitivity and specificity of CTC detection
Spiking of breast cancer cell lines into whole blood ob-
tained from healthy donors, revealed that the recovery
rates of MCF-7 cells were 53%, 21% and 19% for the di-
lutions of 1, 10 and 100 cells per ml, respectively. The
corresponding values were 27%, 19% and 20% for SKBR-
3 and 21%, 21% and 31% for MDA.MB.231 cells.
Spiking of MCF-7 cells into PBMCs showed recovery
rates of 80% for the dilution of 1 cell per 1*106 PBMCs and
100% for the dilutions 10 and 100 cells per 1*106 PBMCs.
No cytokeratin-positive cells could be detected in
PBMCs’ cytospins from healthy donors; however, expres-
sion of both ALDH1 and TWIST could be identified
among PBMCs in all samples analyzed.Figure 1 Control experiments for the specificity of Cytokeratin, ALDH
system. Triple immunofluorescence was performed in cytospin preparation
anti-Cytokeratin (green), anti-ALDH1 (orange) and anti-TWIST (pink) antibod
omitting the corresponding primary antibody and adding the secondary Ig
system (x400).Evaluation of cytospins from HepG2 cells spiked into
PBMCs, prepared as positive and negative controls,
showed high specificity for all the antibodies used in the
current assay (Figure 1). Spiked HepG2 were included as
controls in each separate immunofluorescence experi-
ment performed for patient samples.
Definition of high and low ALDH1 expression levels and
characterization of TWIST sub-cellular localization in
cancer cell lines
HepG2 cell line was used as control for the evaluation of
ALDH1 expression levels. High ALDH1 expression was
evident in the great majority of HepG2 cells; however
cells presenting low or absent ALDH1 expression were
also observed (Figure 2A, Additional file 1A). Measure-
ments (exposure time) for high ALDH1 expression levels
ranged from 5 to 25 (median: 15 ± 0.25), while low
ALDH1 expression levels ranged from 30 to 55 (median:1 and TWIST antibodies in HepG2 cells spiked in PBMCs, ARIOL
s of HepG2 cells spiked in PBMCs from healthy blood donors, using
ies. Negative controls were prepared for each primary antibody, by
G isotype antibody. Cell nuclei were stained with Dapi (blue), ARIOL
Figure 2 Co-expression of Cytokeratin, ALDH1 and TWIST in cancer cell lines and a single CTC detected in a breast cancer patient,
ARIOL system. Triple immunofluorescence was performed in cytospin preparations using anti-CK (green), anti-ALDH1 (orange) and anti-TWIST
(pink) antibodies. Cell nuclei were stained with Dapi (blue). A) HepG2 control cells and three representative breast cancer cell lines, ARIOL system
(x400). B) A CTC (ALDH1high/TWISTnuc phenotype) detected in a metastatic breast cancer patient, ARIOL system (x200).
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was defined at measurements of 25 or lower, whereas
low ALDH1 expression (ALDH1low) was defined at mea-
surements between 30 to 55. The absence of ALDH1 ex-
pression (ALDH1neg) was also evaluated by the use of
negative controls, at measurements of 60 and higher
(range: 60–90, median: 70 ± 0.30). The range of the mea-
surements and the median values with standard error
(SE) within the ALDH1high, ALDH1low and ALDHneg cell
populations are presented in Table 1.
Using the above cut-off points, ALDH1 expression was
subsequently evaluated in three human breast cancer
cell lines: SKBR-3, MCF-7 and MDA.MB.231, represen-
tative of the three breast cancer subtypes: HER2-positive
(Human Epidermal Growth Factor Receptor 2), luminaland basal-like, respectively. ALDH1high, ALDH1low and
ALDHneg cells were detected in all cell lines, with a clear
distinction between high, low and absent ALDH1 ex-
pression levels (Figure 2A, Additional file 1A). Compar-
able median values of measurements within the three
subpopulations (ALDH1high, ALDH1low and ALDHneg)
were confirmed across HepG2 cells and the three breast
cancer cell lines (Table 1).
HepG2 cells were also used as control for the
characterization of TWIST expression. TWIST was lo-
calized in the nucleus (TWISTnuc) in the majority of
HepG2 cells; however cells with cytoplasmic TWIST ex-
pression (TWISTcyt) and cells lacking TWIST expression
(TWISTneg) were also observed. TWISTnuc, TWISTcyt
and TWISTneg cells were also detected in all breast
Table 2 Incidence of CTC phenotypes according to differential expression patterns of ALDH1 and TWIST in patients
with early and metastatic breast cancer
CTC phenotypes
Patients (%) Percentage of CTCs per patient (mean; range) CTCs (%)
Early Metastatic p value Early Metastatic p value Early Metastatic
ALDH1 high 30.8 80.0 0.009 23 (0–100) 75 (0–100) 0.001 38.7 83.5
ALDH1 low/neg 92.3 32.0 0.006 77 (0–100) 25 (0–100) 0.001 61.3 16.5
TWIST nuc 30.8 80.0 0.009 29 (0–100) 73 (0–100) 0.006 32.3 70.3
TWIST cyt/neg 76.9 40.0 0.040 71 (0–100) 27 (0–100) 0.006 67.7 29.7
Chi-square test (Continuity Correction) and Mann Whitney test were used. Only patients with detectable CTCs were included; early setting: 13 patients and 31
CTCs; metastatic setting: 25 patients and 91 CTCs.
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expression of ALDH1 and TWIST was also confirmed
in all cell lines.Expression of ALDH1 and TWIST in CTCs of patients with
early breast cancer
CTCs were detected in 13 out of 80 (16.3%) patients,
with a total of 31 CTCs identified [median No. CTCs/
patient: 1 (range: 1–6)].ALDH1 expression
ALDH1-expressing CTCs were detected in all but one
patient; however CTCs with high ALDH1 expression
(ALDH1high) were observed in 30.8% of patients,
whereas 92.3% had detectable CTCs with low or absent
ALDH1 (ALDH1low/neg) (Table 2). Exclusively ALDH1high
and ALDH1low/neg CTCs were identified in 15.4% and
69.2% of patients, respectively. Regarding the distribu-
tion of phenotypes at the CTC level, ALDH1high and
ALDH1low/neg expression was observed in 38.7% and
61.3% of total CTCs, respectively.TWIST expression
TWIST-expressing CTCs were identified in all but one
patient; in 30.8% of patients CTCs with nuclear TWIST
localization (TWISTnuc) were observed, while 76.9% har-
vested CTCs with cytoplasmic or absent TWIST expres-
sion (TWISTcyt/neg) (Table 2). Exclusively TWISTnuc and
TWISTcyt/neg CTCs were detected in 23.1% and 69.2% of
patients, respectively. Furthermore, the phenotypesTable 3 Incidence of CTC phenotypes according to the co-exp
with early and metastatic breast cancer
CTC phenotypes
Patients (%) Pe
Early Metastatic p value
ALDH1high / TWISTnuc 15.4 76.0 0.001
ALDH1high / TWISTcyt/neg 23.1 24.0 1.000 1
ALDH1low/neg / TWISTnuc 30.8 12.0 0.330 2
ALDH1low/neg / TWISTcyt/neg 61.5 20.0 0.078 5
Chi-square test (Continuity Correction) and Mann Whitney test were used. Only pat
CTCs; metastatic setting: 25 patients and 91 CTCs.TWISTnuc and TWISTcyt/neg were identified in 32.3%
and 67.7% of total CTCs, respectively.ALDH1 and TWIST co-expression
Four different phenotypes could be distinguished accord-
ing to the co-expression of ALDH1 and TWIST at the sin-
gle CTC level (Table 3). ALDH1high/TWISTnuc CTCs
were detected in 15.4% of patients, whereas in 61.5%
ALDH1low/neg/TWISTcyt/neg CTCs were identified. There
were no patients presenting exclusively ALDH1high/
TWISTnuc CTCs, while 53.8% of patients had exclusively
ALDH1low/neg/TWISTcyt/neg CTCs. Moreover, ALDH1high/
TWISTnuc and ALDH1low/neg/TWISTcyt/neg phenotypes
were expressed in 12.9% and 41.9% of total CTCs. The fre-
quency of the two other phenotypes (ALDH1high/TWIST-
cyt/neg and ALDH1low/neg/ TWISTnuc) among patients and
CTCs is also shown in Table 3.
A heterogeneous distribution of specific CTC pheno-
types in individual patients was observed as shown in
Tables 2 and 3, by the differential mean percentages of
CTC subpopulations per patient. This variability is fur-
ther depicted in Table 4 demonstrating the incidence of
different CTC phenotypes in index patients with early
disease.Expression of ALDH1 and TWIST in CTCs of patients with
metastatic breast cancer
The presence of CTCs was documented in 25 out of 50
(50%) patients, with a total of 91 CTCs detected [median
No. CTCs/ patient: 2 (range: 1–21)].ression of ALDH1 and TWIST on single CTCs of patients
rcentage of CTCs per patient (mean; range) CTCs (%)
Early Metastatic p value Early Metastatic
6 (0–50) 64 (0–100) 0.000 12.9 61.5
7 (0–100) 11 (0–100) 0.746 25.8 22.0
3 (0–100) 8 (0–100) 0.152 19.4 8.8
4 (0–100) 16 (0–100) 0.026 41.9 7.7
ients with detectable CTCs were included; early setting: 13 patients and 31
Table 4 Distribution of CTC phenotypes according to ALDH1 and TWIST co-expression in index patients with early and
metastatic breast cancer
Patients ALDH1high/TWISTnuc ALDH1high/TWISTcyt/neg ALDH1low/neg/TWISTnuc ALDH1low/neg/TWISTcyt/neg
Early Total CTC No CTC No (%) CTC No (%) CTC No (%) CTC No (%)
1 3 0 (0) 0 (0) 0 (0) 3 (100)
2 5 0 (0) 0 (0) 0 (0) 5 (100)
3 3 1 (33.3) 0 (0) 2 (66.7) 0 (0)
4 6 3 (50) 1 (16.7) 2 (33.3) 0 (0)
5 6 0 (0) 6 (100) 0 (0) 0 (0)
Metastatic
1 2 2 (100) 0 (0) 0 (0) 0 (0)
2 11 10 (90.9) 1 (9.1) 0 (0) 0 (0)
3 2 1 (50) 0 (0) 1 (50) 0 (0)
4 3 1 (20) 2 (80) 0 (0) 0 (0)
5 21 5 (23.8) 14 (66.7) 0 (0) 2 (9.5)
6 2 0 (0) 0 (0) 0 (0) 2 (100)
7 11 3 (27.2) 2 (18.2) 6 (54.5) 0 (0)
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ALDH1-expressing CTCs were evident in all patients;
however, ALDH1high CTCs were detected in 80% of pa-
tients (p = 0.009, compared to early disease), whereas
ALDH1low/neg CTCs were observed in 32% (p = 0.006)
(Table 2). Exclusively ALDH1high and ALDH1low/neg CTCs
were detected in 68% and 20% of patients (p = 0.006 and
p = 0.009, respectively, compared to early patients). More-
over, ALDH1high and ALDH1low/neg was identified in
83.5% and 16.5% of total CTCs, respectively.
TWIST expression
TWIST-expressing CTCs were also detected in all pa-
tients; however TWISTnuc CTCs were identified in 80%
of patients, while TWISTcyt/neg were observed in 40%
(p = 0.009 and p = 0.040, compared to early disease)
(Table 2). Exclusively TWISTnuc and TWISTcyt/neg CTCs
were detected in 64% (p = 0.040) and 20% (p = 0.009) of
patients. Furthermore, the phenotypes TWISTnuc and
TWISTcyt/neg were observed in 70.3% and 29.7% of total
CTCs, respectively.
ALDH1 and TWIST co-expression
Evaluation of ALDH1 and TWIST co-expression on
single CTCs showed that 76% of patients harvested
ALDH1high/TWISTnuc CTCs (p = 0.001, compared to early
patients), whereas 20% had detectable ALDH1low/neg/
TWISTcyt/neg CTCs (p = 0.078) (Table 3). Exclusively
ALDH1high/TWISTnuc and ALDH1low/neg/TWISTcyt/neg
CTCs were detected in 56% (p = 0.002) and 16% (p = 0.078)
of patients, respectively. In the CTC level, the phenotypes
ALDH1high/TWISTnuc and ALDH1low/neg/TWISTcyt/neg
were confirmed in 61.5% and 7.7% of total CTCs,respectively. The incidence of ALDH1high/TWISTcyt/neg
and ALDH1low/neg/TWISTnuc CTCs was similar to early
disease (Table 3). As shown for early disease, distinct CTC
phenotypes could be observed in individual metastatic pa-
tients (Tables 3 and 4). An ALDH1high/TWISTnuc CTC is
depicted in Figure 2B.
Finally, a positive correlation between ALDH1high and
TWISTnuc expression was confirmed on CTCs of meta-
static patients (p = 0.001, Spearman’s rho analysis),
whereas ALDH1low/neg was associated with TWISTcyt/neg
(p = 0.001).
Discussion
CTCs are considered to be the active source of meta-
static spread; however only a few of these cells are cap-
able of forming metastatic deposits in distant organs.
Indeed, although the presence of CTCs in patients with
breast cancer has been associated with poor prognosis
[2,4], many patients do not relapse even when CTCs are
detected in their blood. Thus, besides detection, further
phenotypic characterization of these cells might provide
additional information for their metastatic potential.
Metastasis is a complex multistep cascade of events
and cancer cells need to be highly equipped in order to
fulfill the metastatic process. CSCs are suggested to have
the ability to self-renew and regenerate the tumor [8].
Moreover, EMT has been linked to cancer progression
and acquisition of stem cell-like properties [32]. Thus,
CTCs co-expressing stem cell and EMT markers could
be actively involved in tumor progression. We have re-
ported that the stemness markers CD44/CD24 and
ALDH1 are expressed in CTCs of patients with meta-
static breast cancer [14]. Moreover, we have recently
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were frequently expressed on CTCs of patients with
early and metastatic breast cancer [22]. In this study, we
developed a new methodology to investigate the expres-
sion pattern of ALDH1 and TWIST on CTCs of breast
cancer patients and to evaluate their co-expression at
the single CTC level.
The expression of ALDH1 in primary tumors has been
associated with poor patient outcome in several cancers,
including breast cancer [10,12,33]. Moreover, differential
ALDH1 expression levels have been demonstrated and a
positive correlation has been suggested between high
ALDH1 and worse clinical outcome [34-36]. High
ALDH1 protein expression has also been associated with
high ALDH enzymatic activity, a putative marker for
CSCs [37]. Accordingly, in the present immunofluores-
cence assay, a quantitative analysis of ALDH1 expression
levels by the use of the ARIOL system software was
employed [22].
With the provided quantification method, a clear dis-
tinction between high and low ALDH1 expression was
demonstrated in HepG2 control cell line. The evaluation
of ALDH1 expression in three breast cancer cell lines
representative of HER2-positive, luminal and basal-like
subtypes, further confirmed the presence of ALDH1high,
ALDH1low and ALDHneg cells within each cell line. The
comparable range and median expression values of each
cell subpopulation among all cell lines verified the ob-
jectivity of ALDH1 quantification irrespectively of the
specific breast cancer subtype and allowed its application
on patient samples.
Interestingly, although ALDH1-expressing CTCs were
identified in almost all CTC-positive patients, the pat-
tern of ALDH1 expression differed among CTCs in both
clinical settings. Moreover, ALDH1high CTCs were more
frequently observed in metastatic patients, whereas
ALDH1low/neg CTCs were mainly detected in patients
with early disease. This observation suggests that
ALDH1high CTCs predominate during disease progres-
sion and leads to the assumption that CTCs bearing
stemness characteristics may have an active role in the
metastatic process. We have previously reported a lower
frequency of ALDH1high CTCs in patients with meta-
static breast cancer, which could be explained by the
lower number of patients included in that study, as well
as by the different methodologies used for the titration
of ALDH1 expression [14].
TWIST is a transcription factor with a pivotal role in
EMT induction, both in normal and cancer cells [38].
The expression of TWIST in breast tumors has been
correlated to increased metastatic potential and poor
survival [19]. In the present study, we further analyzed
the subcellular localization of TWIST on CTCs, since ef-
ficient nuclear localization is essential for a protein tooperate as an activator and/or repressor of transcription
of target genes [39]. Furthermore, Yuen et al. showed
that nuclear TWIST localization predicted the meta-
static potential of prostate tumors [40], whereas in
esophageal squamous cell carcinoma, it was associated
with lymph node metastasis [41]. The data presented in
the current study are in agreement with our previously
reported results showing that TWIST is expressed in the
majority of CTCs derived from patients with breast can-
cer [22]. Here we further show that CTCs present a dif-
ferential TWIST subcellular localization pattern. In
addition, we demonstrate that TWISTnuc CTCs were
more frequently detected in metastatic patients, while in
early disease TWISTcyt/neg CTCs were mainly observed.
This observation suggests that TWIST localization may
be related with functional cellular properties during the
different stages of the disease. It could be hypothesized
that TWISTnuc CTCs are undergoing EMT and selected
during disease progression. In accordance, a recent study
showed that CTCs of breast cancer patients exhibit dy-
namic changes in epithelial and mesenchymal compos-
ition and that the presence of CTCs in EMT state was
associated with disease progression [42].
Previous studies have also reported the expression of
ALDH1 and TWIST on CTCs of early and metastatic
breast cancer patients [27,43], though at a lower fre-
quency. This could be attributed to methodological dif-
ferences, since the AdnaTest used in these studies
analyzes mRNA expression in CTC-positive blood sam-
ples, whereas in the current assay protein expression on
single CTCs is evaluated.
Using the present assay, four different CTC pheno-
types were identified according to the simultaneous
evaluation of both markers. An interesting finding was
the considerable inter- and intra-patient heterogeneity
regarding the frequency of distinct CTC subpopulations
either in the early or the metastatic disease setting.
Moreover, a differential distribution of phenotypes was evi-
dent comparing the two groups of patients; ALDH1high/
TWISTnuc CTCs were more prominent among metastatic
patients, whereas the ALDH1low/neg/TWISTcyt/neg pheno-
type predominated in patients with early disease. The
finding that ALDH1high and TWISTnuc phenotypes were
mainly co-expressed in the same CTC, as well as their
positive correlation shown in metastatic disease, further
supports the hypothesis of a link between stemness and
EMT characteristics on cancer cells. [44,45]. This is also
in agreement with recent studies showing that overex-
pression of TWIST induces ALDH1 expression in cell
lines [46,47].
In the current study, CTCs bearing high ALDH1 ex-
pression, along with nuclear TWIST localization, are not
proven to be cancer stem cells undergoing EMT. Further
experiments with functional assays would be required to
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less, this is beyond the scope of the current report which
aimed in the evaluation of previously suggested stemness
and EMT markers on single CTCs. The higher preva-
lence of these markers in metastatic breast cancer pa-
tients suggests that they could possibly distinguish a
subpopulation of CTCs with aggressive biological prop-
erties. Therefore, phenotypic characterization of CTCs
according to the expression of ALDH1 and TWIST
merits further evaluation in a larger cohort of patients,
in order to investigate the clinical significance of the
above findings.
Conclusions
The current study provides a new methodology for the
evaluation of ALDH1 and TWIST co-expression on sin-
gle CTCs of patients with breast cancer. Using this assay,
distinct CTC phenotypes, according to ALDH1 expres-
sion levels and TWIST subcellular localization, were
designated in patients with early and metastatic breast
cancer. The higher incidence of CTCs bearing putative
stem cell and EMT traits in metastatic disease, suggests
that these characteristics may prevail on CTCs during
disease progression. A correlation between stemness and
EMT features was further confirmed on single CTCs.
Additional file
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all cell lines, by staining with anti-ALDH1 antibody (orange). B) TWISTnuc,
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anti-TWIST antibody (pink). Cell nuclei were stained with Dapi (blue).
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